Mukul Agarwal picks up a ₹29 crore, 3.43% stake in Gaudium IVF & Women Health
Mukul Agarwal has picked up a ₹29 crore, 3.43% stake in Gaudium IVF & Women Health — a fertility-care chain trading at a real discount to its own listed peer group, in a sector with essentially no direct pure-play listed competitor in India.
Gaudium IVF and Women Health Ltd - Share price: ~₹108.72 (as of 19 Jun 2026 — check the live price) - Market cap: ~₹1,102 crore - P/E: ~32.35x (as of 19 Jun 2026) — a 32% discount to its peer group's median of ~47.63x (peers include Apollo Hospitals, Fortis Healthcare, Max Healthcare, Rainbow Children's Medicare, and the US-listed Progyny)
What the company does, and why the stake is notable
Gaudium IVF, founded in March 2015 by Dr. Manika Khanna, runs a clinician-led fertility clinic chain with 17 years of clinical heritage, operating an asset-light hub-and-spoke model — 8 hubs and 28 spokes as of the August 2026 quarter, including international spokes in Paris, Nigeria and Sydney. It listed on Indian exchanges in February 2026 at a ₹75-79 price band. Patients pay anywhere from ₹2 lakh for a basic IVF cycle to ₹20 lakh for complex cases, averaging around ₹3.5 lakh per patient.
Agarwal added a fresh 25,00,000-share position worth ₹39.62 crore in the recent shareholding-pattern update — on top of an earlier stake reported at ₹29 crore/3.43% — a specialty-healthcare bet in a category most portfolios don't have direct listed exposure to.
A first-mover in a category with no direct listed peer
There is no directly listed pure-play IVF competitor in India — Gaudium competes with unlisted chains (Indira IVF, Nova IVF) and gets valued against broader hospital/healthcare names instead. Gaudium retains a 27.05% net margin, versus aggregator-model US player Progyny's 4.46% — a structurally more profitable model, since Gaudium owns and runs its own clinical facilities rather than aggregating bookings. Its clinical outcomes (62% first-attempt pregnancy success, 85% cumulative) are pitched as at par with global standards, and it claims to be the first IVF chain in India using AI-powered embryology (SiD for sperm selection, ERICA for embryo grading), showing an ~8% improvement in first-attempt success since integration in April 2026.
Management's own guidance, in full
- 30% revenue growth guided for FY27 — confirmed explicitly in the Q1 FY27 earnings call Q&A ("Yes, right"), against historical growth of ~30% versus an industry CAGR of just 10-12% - EBITDA and PAT to be sustained at adjusted FY26 levels by year-end — no specific rupee target given - 10 new IVF hubs planned for FY27 (South Extension already commissioned July 2026; Gurgaon and Nagpur targeted within weeks of the August earnings call; remaining 7 by March 2027), funded via a ₹25 crore FY27 capex envelope (~₹2.5 Cr per hub) from IPO proceeds and internal accruals - 8 additional new centres planned for FY28, 1 more for FY29, per the original listing roadmap - Gaudium Women Hospital, Lucknow: board-approved, project cost up to ₹15 crore, funded from internal accruals (not IPO money), commercialisation targeted FY28-29 — a strategic expansion beyond pure-play IVF into gynaecology, oncology screening and surgery - Patient-financing tie-up with HDFC Bank to push into Tier 2/3 markets
This is management's own forward-looking statement, not a verified fact or a promise — the Q1 FY27 print already shows the execution risk: EBITDA margin fell sharply to 12.5% (from 29% a year earlier) due to deliberate front-loaded expansion spend, though management says adjusted EBITDA margin (excluding one-off costs) still ran around 27.63%.
Risks flagged by management and analysts themselves
- ART and Surrogacy Act implementation is patchy — most state ART boards aren't fully formed, some lack bank accounts to process fees — tempering the regulatory-consolidation tailwind management had leaned on, by the company's own admission in the call. - Execution risk on the 10-hub FY27 rollout — only one hub commissioned as of the August call, with nine still to go. - Underperforming legacy centres: Ludhiana (small market), Srinagar (seasonal), and the recently relocated Patna centre, whose revenue ramp at the new location is still unproven. - Q1 seasonality (extreme heat suppresses patient demand) makes quarter-to-quarter growth numbers volatile and easy to misread in isolation.
The valuation angle worth remembering A 32% P/E discount to a peer group of far larger, more diversified hospital chains is real — but a sharp Q1 FY27 margin dip (29% to 12.5%) on the same expansion this discount is supposed to reward shows the discount also reflects genuine near-term execution risk, not just an inefficiency in market pricing.
Note: I am not a SEBI-registered investment advisor. This article is for educational purposes only and is not investment advice. Please consult a registered financial advisor before making investment decisions.
Sources
- https://www.whalesbook.com/news/English/stock-investment-ideas/Mukul-Agarwal-Bets-indian-rupee125-Cr-on-High-Efficiency-SMEs-Amid-Market-Risks/69f2b58808235f0c2a1cb4ca - https://ipocentral.in/gaudium-ivf-vs-indira-ivf-vs-global-peers/ - https://www.valueresearchonline.com/stocks/377749/gaudium-ivf-and-women-health-ltd/ - https://www.indiainfoline.com/company/gaudium-ivf-and-women-health-ltd/peer-comparison - Gaudium IVF Q1 FY27 earnings call transcript